Prothena Corporation plc has released a presentation detailing its focus on delivering life-saving therapies for diseases caused by protein dysregulation, including Alzheimer's disease, Parkinson's disease, and Transthyretin amyloidosis. The presentation highlights the company's multiple ongoing clinical programs, including two partnered Phase 3 programs, one partnered Phase 2 program, one partnered Phase 1 program, and one wholly-owned Phase 1 program. Prothena has established strong collaborations with major companies such as Bristol Myers Squibb, Novo Nordisk, and Roche. The presentation also emphasizes Prothena's expertise in epitope mapping and disease-driven antibody engineering, aiming to optimize therapeutic outcomes for patients. You can access the full presentation through the link below.